Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia

BackgroundInfants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim...

Descrición completa

Detalles Bibliográficos

Principais autores:	Laurence C. Cheung, Rebecca de Kraa, Joyce Oommen, Grace-Alyssa Chua, Sajla Singh, Anastasia M. Hughes, Emanuela Ferrari, Jette Ford, Sung K. Chiu, Ronald W. Stam, Ursula R. Kees, Sébastien Malinge, Rishi S. Kotecha
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2021-04-01
Series:	Frontiers in Oncology
Assuntos:	infant acute lymphoblastic leukemia KMT2A MLL carfilzomib PER cell lines
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fonc.2021.631594/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!